In 2024, approximately ****** Zika virus infections were reported in Latin America and the Caribbean, up from ****** cases reported a year earlier. This represents an overall decrease after peaking at over ******* infections in 2016. Brazil was by far the country with the highest number of Zika infections in Latin America as of 2024. Tropical diseases in Latin America Tropical diseases are illnesses prevalent in tropical and subtropical climates, where humidity and high temperatures are widespread. In 2024, there were approximately ******* cases of Chikungunya and in the beggining of 2025, over ****million cases of dengue in Latin America, with Brazil accounting for the highest number. With more than ******* infections, Brazil recorded the highest number of suspected and confirmed cases of malaria in the region in 2023. Zika virus in Brazil Brazil recorded over ****** cases of Zika virus infections in 2024. With around ******* cases, 2016 had the highest number of Zika infections in the country during the period between 2015 and 2024. In 2022, over ** percent of the Zika cases in Brazil occurred in Rio Grande do Norte, a state located in the northeast. With more than *** affected children as of 2021, the state of Pernambuco had the greatest number of verified cases of congenital Zika virus syndrome (CZS). CZS refers to a range of birth defects caused by Zika infection during pregnancy.

In 2024, Brazil reported ****** cases of Zika virus disease, making it the Latin American country with the most Zika infections among selected nations that year. Argentina ranked second, with ****registered Zika virus infections.

In 2024, South America reported a total of ****** cases of Zika virus disease, making it the Latin American sub-region with the highest number of Zika infections. That year, Central America reported *** cases. In 2024, Brazil was the country with the highest number of Zika cases in Latin America and the Caribbean.

Values in brackets represent the mean estimates under the assumption of a 0.1:1 and 10:1 ZIKV-dengue ratios.

ZIKAV-related publications up to December 2017, retrieved from WoS, PubMed, and Scopus. (CSV 1513 kb)

The Zika virus testing market, while exhibiting a smaller market size compared to broader infectious disease diagnostics, presents a significant opportunity driven by factors such as ongoing outbreaks in certain regions, heightened public health concerns, and advancements in diagnostic technologies. The market, estimated at $150 million in 2025, is projected to experience a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching approximately $260 million by 2033. This growth is propelled by increased government funding for disease surveillance and control programs, particularly in endemic regions, and the development of rapid, point-of-care diagnostic tests that allow for faster diagnosis and containment of outbreaks. Key market segments include diagnostic centers, hospitals, and pathology labs, with molecular tests and serologic tests forming the core testing methodologies. While constraints like the sporadic nature of outbreaks and the availability of alternative diagnostic solutions exist, the market is poised for growth due to sustained research and development efforts focused on improving test accuracy, sensitivity, and affordability. The leading companies in this space, including Chembio, Quest Diagnostics, ARUP Laboratories, and Abbott Molecular, are actively contributing to market growth through continuous innovation and expansion of their product portfolios. Geographic distribution is heavily influenced by the prevalence of Zika virus, with North America and regions of Latin America and the Asia-Pacific showing higher demand due to historical outbreaks and ongoing surveillance activities. Future market expansion will hinge upon effective disease control strategies, ongoing surveillance programs, and continued development of more sensitive, rapid, and cost-effective diagnostic tools that can facilitate early detection and prompt intervention. The market's growth trajectory remains promising despite inherent challenges associated with infectious disease diagnostics.

In 2024, Bolivia reported a total of *** cases of Zika virus disease, down from *** infections registered a year earlier. During the period analyzed, 2017 and 2018 were the years with most Zika infections in the South American country, with ***** cases each. In the last year depicted, Brazil was the country with the highest number of Zika virus infections in Latin America.

How does the news media respond to health emergencies abroad? Between 2015 and 2018, Zika virus spread rapidly throughout Latin America before arriving in the continental United States. Despite the risks to adults and newborns, it is unclear how media coverage developed and framed the threat for its audience. In this paper, we argue that while the frequency of coverage was responsive to infections, its content failed to promote proactive health behaviour. To assess these claims, we analyse each of 442 articles dealing with Zika virus published by The New York Times from 2015–18. We find that the amount of coverage reflected infections but did not change once the disease emerged in the US. Furthermore, content analysis using Linguistic Inquiry and Word Count (LIWC) software reveals that coverage emphasised differences between communities (those affected and those at home) and that present and past time orientations dominated coverage as opposed to future time orientations.

Zika Virus Testing Market Outlook

According to our latest research, the global Zika virus testing market size in 2024 stands at USD 243.7 million, reflecting the growing demand for rapid and accurate diagnostic solutions in the wake of recurring Zika outbreaks. The market is projected to expand at a robust CAGR of 6.1% from 2025 to 2033, reaching a forecasted value of USD 415.2 million by 2033. This growth is primarily driven by technological advancements in diagnostic methods, increased awareness of mosquito-borne diseases, and the ongoing need for efficient surveillance and containment strategies. As per our latest research, the market’s upward trajectory is further supported by government initiatives and international collaborations aimed at controlling the spread of Zika virus, particularly in high-risk regions.

One of the most significant growth factors for the Zika virus testing market is the persistent threat posed by the virus in tropical and subtropical areas, where Aedes mosquitoes are prevalent. The cyclical nature of Zika outbreaks, coupled with the virus’s association with severe birth defects such as microcephaly and neurological complications like Guillain-Barré syndrome, has heightened the urgency for early detection and intervention. Public health authorities and global organizations, including the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), continue to emphasize the importance of robust surveillance and diagnostic infrastructure. These efforts have resulted in increased funding for research and development of innovative testing solutions, thereby expanding the market’s scope and accessibility.

Another crucial driver is the evolution of diagnostic technologies, which has significantly improved the sensitivity, specificity, and turnaround time of Zika virus tests. The shift from conventional serological assays to advanced molecular diagnostic techniques, such as real-time PCR and next-generation sequencing, has enabled healthcare providers to detect Zika infections with greater accuracy, even during the early stages of infection. Furthermore, the integration of automation and digital health platforms in diagnostic laboratories is streamlining workflows and reducing human error, ultimately enhancing the reliability and scalability of Zika virus testing. This technological progress is particularly beneficial for resource-limited settings, where rapid and portable diagnostics are essential for effective outbreak management.

Moreover, the growing emphasis on travel-related screening and prenatal diagnostics is fueling the demand for Zika virus testing across various end-user segments. International travel and migration have been identified as key factors in the cross-border transmission of the virus, prompting governments to implement stringent screening protocols at airports and border checkpoints. Pregnant women and women of childbearing age are a primary focus for Zika testing, given the virus’s severe implications for fetal development. As a result, hospitals, diagnostic laboratories, and research institutes are investing in comprehensive testing panels and multiplex assays to differentiate Zika from other co-circulating arboviruses, such as dengue and chikungunya. This multifaceted approach is expected to further propel the market’s growth in the coming years.

Regionally, the Latin America segment remains at the forefront of the Zika virus testing market, accounting for the largest share in 2024 due to the high incidence of Zika cases and proactive government responses in countries such as Brazil, Colombia, and Mexico. However, the Asia Pacific region is rapidly emerging as a key growth area, driven by increasing awareness, expanding healthcare infrastructure, and rising investments in public health surveillance. North America and Europe continue to play a pivotal role in research and development, with several leading diagnostic companies headquartered in these regions. The Middle East & Africa, while currently representing a smaller share, is expected to witness steady growth as international aid and technical support are directed towards strengthening diagnostic capabilities.

Map Journal created from a variety of CDC (Centers for Disease Control and Prevention), PAHO (Pan American Health Organization), ECDC (European Centre for Disease Prevention and Control), and WHO (World Health Organization) resources to tell and distinguish ways in which we have and will be impacted by the Zika Virus... This document looks to answer the below questions and provide insight and understanding of the situation in the America's:

• Why do we care about the Zika virus?
• What happens when babies have microcephaly?
• What is the Zika virus?
• What transmits the Zika virus? and What is the Global distribution of the mosquito?
  
• What is the approximate distribution for the habitat of the mosquito?
• What is the timeline of the disease?
• What are the symptoms?
• What is a methodology we can build to track the disease? And how can we easily share the methodology?
• How can we prevent getting the disease?
• Centers for Disease Control & Prevention Historical US Zika Cases
  
• What does the future look like in the United States?
• What does the future look like in Central and South America?
  

Key Resource Links:

• https://www.cdc.gov/zika/geo/pregwomen-uscases.html
  
• https://www.cdc.gov/zika/geo/united-states.html
  
• http://www.marketwatch.com/story/what-exactly-is-the-zika-virus-and-why-should-you-care-2016-01-25
• http://www.cbc.ca/news/health/zika-who-monday-1.3428485
• http://www.statnews.com/2016/01/15/zika-florida-texas-disease-vector-study/
• http://www.nbcnews.com/storyline/zika-virus-outbreak/zika-virus-outbreak-who-chief-convenes-emergency-committee-meeting-n505706
• http://elifesciences.org/content/4/e08347#fig-data-major-datasets
• http://elifesciences.org/content/4/e08347
• http://www.travelpulse.com/news/impacting-travel/survey-more-than-half-of-respondents-would-not-travel-to-zika-affected-regions.html
• http://www.theatlantic.com/health/archive/2016/02/the-past-present-and-future-of-zika/459585/
  

The Zika virus diagnostic market, valued at $146.5 million in 2025, is poised for significant growth. While the provided CAGR is missing, considering the ongoing need for diagnostic tools and the potential for future outbreaks, a conservative estimate of a 5% CAGR (Compound Annual Growth Rate) from 2025 to 2033 is plausible. This translates to substantial market expansion, driven by factors such as increasing awareness of Zika virus transmission and its associated complications like microcephaly. The market is segmented by test type (molecular and serologic) and application (diagnostic centers, hospitals, pathology labs), with molecular tests currently dominating due to their higher accuracy and speed. Geographical distribution shows a significant concentration in regions with historical Zika outbreaks like North and South America, but growth is expected across all regions, especially in developing nations with limited healthcare infrastructure where rapid diagnosis is crucial. The presence of major pharmaceutical companies such as Bharat Biotech, Sanofi, and GlaxoSmithKline indicates significant industry investment in research and development, further fueling market expansion. However, challenges persist including the intermittent nature of outbreaks, the development of cost-effective diagnostic solutions for widespread adoption, and potential regulatory hurdles affecting market penetration. Further fueling market growth are advancements in point-of-care diagnostics, offering faster and more accessible testing, particularly in remote areas. Improved understanding of the virus's epidemiology is also contributing to more targeted surveillance and testing strategies. However, restraints include the unpredictable nature of outbreaks and the need for continuous research to improve diagnostic accuracy and affordability. A key challenge lies in establishing effective long-term surveillance programs to ensure timely detection and response to potential future outbreaks. The market will likely see increased competition among diagnostic manufacturers, leading to innovation in technology and pricing, which will overall benefit patients and healthcare systems globally.

ZIKAV-related patents with earliest priority date up to 12/31/2017 (XLSX 1728 kb)

The Zika Virus Testing Market Report is Segmented by Test Type (Molecular Tests, Serologic Tests, PRNT), Sample Type (Blood/Serum, Urine, Saliva & Others), End-User (Hospitals & Clinics, Public-Health/Diagnostic Laboratories, Point-Of-Care Settings & Home Testing, Research Institutes), and Geography (North America, South America, Europe, APAC, Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

In 2023, Brazil reported around ****** cases of Zika virus disease, up from around ****** infections registered a year earlier. During the period analyzed, 2016 was the year with the most Zika infections in the South American country, with nearly ******* cases. Brazil is the most affected country in Latin America The Zika virus disease is mosquito borne and transmitted mainly through the bites of the Aedes aegypti, a mosquito also associated with dengue. Symptoms are often mild and include fever, headache, rashes, and joint pain. However, a Zika infection during pregnancy can cause certain congenital disorders. Between 2021 and 2023, Zika infections nearly doubled in Latin America, with Brazil reporting the highest number of Zika cases, followed by Bolivia and Belize in 2023. As of 2022, the most affected Brazilian region was the Northeast, where the majority of probable Zika cases were recorded. Zika testing market value worldwide As there is still no specific cure, vaccine, or treatment for Zika infections, preventing mosquito bites and safe sexual practices protect against this infection. Moreover, testing for Zika is recommended when symptoms appear after traveling to countries where the disease is still prevalent. Globally, the value of the Zika virus testing market has been increasing since 2020 and is expected to reach over *** million U.S. dollars by 2026.

The Zika virus therapeutic market, while currently relatively small, exhibits significant growth potential fueled by several key factors. The market size in 2025 is estimated at $760.4 million, demonstrating a substantial base for future expansion. A compound annual growth rate (CAGR) of 5.8% from 2025 to 2033 projects a market value exceeding $1.2 billion by 2033. This growth is driven by increasing prevalence of Zika virus infections in tropical and subtropical regions, coupled with ongoing research and development efforts focused on developing effective therapeutics. The market is segmented by drug type (Acetaminophen, Other NSAIDs being the primary types) and distribution channels (Institutional Pharmacies, Retail Pharmacies, and Others). The significant presence of major pharmaceutical companies like Johnson & Johnson, Aurobindo Pharma, and others indicates a high level of industry investment and confidence in the market's future. Increased government funding for research, heightened public awareness due to past outbreaks, and potential for future epidemics contribute to the positive outlook. However, challenges remain, including the relatively low awareness of the Zika virus and the complexities associated with developing effective treatments for viral infections. Furthermore, the unpredictable nature of outbreaks and the potential for the emergence of resistant strains could pose hurdles to long-term market growth. The regional distribution of the market mirrors the geographical prevalence of the Zika virus. North America and regions in South America and Asia-Pacific will likely see the highest market penetration due to historical and ongoing infection rates. While data for individual regions is not available, it is expected that North America will hold a substantial market share, followed by regions with high endemic rates of Zika infection, indicating a localized concentration of demand. Europe and the Middle East & Africa regions are expected to have comparatively smaller market shares but still contribute to market growth, particularly as preventative measures and treatment options continue to develop. The competitive landscape is characterized by a mix of large multinational pharmaceutical companies and smaller specialized biotech firms, leading to innovations in both treatment approaches and distribution strategies. The market’s future trajectory hinges on continued research success, robust public health interventions, and successful commercialization of effective Zika virus therapeutics.

Snapshot img

Zika Virus Therapeutics Market Size 2024-2028

The zika virus therapeutics market size is forecast to increase by USD 4.17 billion at a CAGR of 4.5% between 2023 and 2028.

The market is experiencing significant growth due to several key factors. One of the primary drivers is the availability of serology kits for the qualitative diagnosis of Zika virus infection. This allows for early detection and treatment of the disease, which is crucial given the asymptomatic nature of the infection in many cases. Additionally, increasing efforts by both government and private organizations to facilitate vaccine development are contributing to market growth. The lack of effective treatments and vaccines for Zika virus infection presents a significant challenge, but ongoing research and development efforts are expected to lead to new therapeutic options in the near future. Overall, the market is poised for substantial growth In the coming years as the global community continues to grapple with this emerging infectious disease.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market represents a significant response to the global health concern posed by the Zika virus, primarily transmitted by Aedes mosquitoes. The virus is associated with severe birth defects, including microcephaly, and can also be contracted through sexual contact from an infected partner. The clinical manifestations of Zika virus infection include rash, malaise, headache, low-grade fever, and arthralgia. As of now, there are no approved vaccines or specific antiviral drugs for treating Zika virus infections.
These efforts include the development of small molecule inhibitors and other therapeutic approaches. The Zika virus market is expected to grow substantially due to the ongoing epidemic and the high unmet medical need for effective treatments. Additionally, the potential cross-reactive applications of Zika virus therapeutics in other mosquito-borne diseases, such as dengue, malaria, typhoid, and pneumonia, further expand the market's scope.

How is this Zika Virus Therapeutics Industry segmented and which is the largest segment?

The zika virus therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Acetaminophen
  Other NSAIDs


Geography

  North America

    Canada
    US


  Europe

    Denmark


  Asia

    China
    India


  Rest of World (ROW)

By Product Insights

The acetaminophen segment is estimated to witness significant growth during the forecast period.

Zika virus, a mosquito-borne infection from the Flavivirus family, is linked to severe birth defects, primarily microcephaly and congenital disabilities. The primary mode of transmission is through the bite of Aedes mosquitoes, but sexual contact can also spread the virus to the mother and fetus. Acetaminophen, a common analgesic and antipyretic, is used for symptomatic relief of fever, rash, malaise, headache, arthralgia, and pruritic maculopapular rashes. As a first-line therapy for pain conditions, acetaminophen is the most widely used medication. Its antipyretic effect helps reduce fever associated with Zika virus infection. However, potential treatments for Zika virus infection go beyond symptomatic relief.

Researchers are exploring small molecule inhibitors, such as Emricasan, which exhibits antiviral activity against Zika virus in laboratory studies by inhibiting host protein caspase-8 and blocking viral replication. Drug development processes involve safety and efficacy clinical trials for potential treatment options, addressing viral resistance development, broader efficacy, and safety profile. Novel drug targets and therapeutic approaches are being investigated, along with repurposing existing drugs. Market segmentation includes oral, injection, antiviral medications, vaccines, and medical diagnostic testing for severe cases. Driving factors include public health concerns, neurological complications, and commercial opportunities. Reimbursement policies and advances in technology, such as computational modeling and genomic analysis, are also crucial aspects of the market.

Get a glance at the Zika Virus Therapeutics Industry report of share of various segments Request Free Sample

The acetaminophen segment was valued at USD 8.2 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

Asia is estimated to contribute 35% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market

BackgroundOver 400,000 people across the Americas are thought to have been infected with Zika virus as a consequence of the 2015–2016 Latin American outbreak. Official government-led case count data in Latin America are typically delayed by several weeks, making it difficult to track the disease in a timely manner. Thus, timely disease tracking systems are needed to design and assess interventions to mitigate disease transmission.Methodology/Principal FindingsWe combined information from Zika-related Google searches, Twitter microblogs, and the HealthMap digital surveillance system with historical Zika suspected case counts to track and predict estimates of suspected weekly Zika cases during the 2015–2016 Latin American outbreak, up to three weeks ahead of the publication of official case data. We evaluated the predictive power of these data and used a dynamic multivariable approach to retrospectively produce predictions of weekly suspected cases for five countries: Colombia, El Salvador, Honduras, Venezuela, and Martinique. Models that combined Google (and Twitter data where available) with autoregressive information showed the best out-of-sample predictive accuracy for 1-week ahead predictions, whereas models that used only Google and Twitter typically performed best for 2- and 3-week ahead predictions.SignificanceGiven the significant delay in the release of official government-reported Zika case counts, we show that these Internet-based data streams can be used as timely and complementary ways to assess the dynamics of the outbreak.

Market Overview The global Zika virus testing market is poised for significant growth in the coming years. With a market size of around $XXX million in 2025, it is projected to grow at a CAGR of XX%, reaching a value of $XXX million by 2033. The rise in Zika virus cases, particularly in tropical and subtropical regions, is a key driver for the market's expansion. Additionally, advancements in testing technologies, such as real-time PCR and serological assays, have improved the accuracy and accessibility of Zika virus diagnosis. Market Segmentation and Competitive Landscape The Zika virus testing market is segmented based on application (diagnostic, blood screening, and research) and type (nucleic acid amplification testing, serologic testing, and molecular diagnostics). Major players in the market include Chembio, Quest Diagnostics, ARUP Laboratories, Luminex, Siemens, Abbott Molecular, Hologic, ELITech Molecular Diagnostics, EUROIMMUN US, Creative Diagnostics, Vela Diagnostics, InBios International, Primerdesign, and Altona Diagnostics. These companies are investing in research and development to enhance their testing capabilities and expand their product offerings. Geographically, the market is divided into North America, South America, Europe, the Middle East & Africa, and Asia Pacific. North America and Europe currently hold the largest market share due to the high prevalence of Zika virus and robust healthcare systems.

These data represent mosquito trap site results in the District of Columbia from 2016 to 2018. Trap locations are considered approximate address and/or the “nearest” street address or block to the stated coordinates in the data. Visit Fight the Bite: Protecting the District of Columbia from Mosquitoes- a collection of the 2016-2018 Arbovirus Surveillance Program conducted annually by DC Health, Health Regulation & Licensing Admin., Animal Services Div.Mosquitoes have the potential to spread harmful diseases. During the annual mosquito season in Washington DC, usually from April – October, DC Health deploys surveillance and mitigation methods to control the mosquito population in the District. DC Health (also known as the D.C. Department of Health or formerly DOH) has been trapping and testing mosquitoes for West Nile virus (WNV) for well over a decade. Starting in 2016, and in response to the Zika outbreak in Latin America and the Caribbean, DC Health substantially increased mosquito monitoring activities across the city. There were a total of 28 sites and 36 traps across the 8 wards. Data was submitted to the Centers for Disease Control MoquitoNet Portal.Note: the 2017 analysis does not include data for October. This is because October of 2017 would have skewed the results far too much based on a few variables that occurred. For example, the number of traps which had failed by the end of the season.Mosquito species in Washington, D.C.:Culex Pipiens, Salinarius and Culex Restuan: spread West Nile VirusAedes aegypti : according to the Centers for Disease Control (CDC), health experts have determined this species to be the most competent vector, capable of transmitting Zika to the human population. To date, none of the Aedes aegypti trapped in Washington, D.C. have been found to carry the Zika virus.Aedes albopictus: capable of spreading Zika to people. However, health experts are still learning whether it is likely to do so as it appears at this time, it is not as competent a vector for transmitting Zika as is the Aedes aegypti. Just because a mosquito can carry the virus does not mean that it will cause disease. So far, none of the Aedes albopictus trapped in Washington, D.C. have been found to carry the Zika virus.Aedes japonicus: normally found in South Florida, is present in D.C. in small numbers. Presently there is no indication that they are competent vectors for spreading Zika to the human population.